Nanjing, China · Founded 2018 · In IPO Registration
Developer and provider of innovative antiviral and oncology therapies designed for unmet clinical needs in viral infections, cancer, and inflammatory diseases. Zenshine Pharmaceuticals (Nanjing) Group is based in Nanjing, China and was founded in 2018. Its last reported valuation was $354 million in Jan 2026. It has raised $127 million.
Last reported valuation
$354.4M
Oct 2026
Priced at
—
Total raised
$126.6M
Last round
—
No prints on record
No secondary trades in Zenshine Pharmaceuticals (Nanjing) Group shares have been recorded yet. When market activity lands it appears here as monthly aggregates and, for platform-recorded trades, dated prints.
Pro members can request priority coverage with a 48-hour turnaround.
Free account
More of Zenshine Pharmaceuticals (Nanjing) Group with a free account
·The complete investor list: 21 names
·Watch Zenshine Pharmaceuticals (Nanjing) Group: the Monday email on marks, rounds and moves
Where Zenshine Pharmaceuticals (Nanjing) Group prices come from
Secondary marks are indicative month-end price levels observed across secondary-market trading venues — a level, not a trade — and are the market input to the PrivateMarketView mark. Private share prices aren’t published anywhere. Aggregate figures combine multiple reporting channels — direct participant reports, platform transactions, third-party market intelligence — at monthly granularity. Individually dated prints are a Pro feature and are shown only for transactions recorded on our own platform. Third-party-reported trades are never republished individually, at any tier. Verified prints (✓) have been confirmed against a second source. Prints marked SPV or Forward reflect the structure’s pricing, which can differ from direct share transfers of Zenshine Pharmaceuticals (Nanjing) Group stock.
